# Cephalosporins

This is a subcategory of Infectious Disease Agents.

## Formulary

### Preferred

| Preferred             | Generic Name | Quantity | Time (Days) |
| :-------------------- | :----------- | :------: | :---------: |
| Cefadroxil            |              |          |             |
| Cephalexin 250, 500 MG |              |          |             |
| Cefaclor IR             |              |          |             |
| Cefaclor ER           |              |          |             |
| Cefaclor Susp <sup>AR</sup>     |              |          |             |
| Cefprozil             |              |          |             |
| Cefprozil Susp <sup>AR</sup>     |              |          |             |
| Cefuroxime            |              |          |             |
| Cefdinir              |              |          |             |

### Non-Preferred

| Non-Preferred          | Generic Name | Quantity | Time (Days) |
| :--------------------- | :----------- | :------: | :---------: |
| Cephalexin 750 MG      |              |          |             |
| Cefpodoxime            |              |          |             |
| Cefixime Cap           |              |          |             |
| Cefixime Susp <sup>AR</sup>       |              |          |             |
| Suprax Chewable Tab <sup>AR</sup> |              |          |             |

## Length of Authorizations

Based on indication

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **3 days** with at least **one preferred** antibiotic
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Information

- Requests may be authorized if:
    - The infection is caused by an organism resistant to ALL preferred antibiotics (must provide diagnosis and any culture/sensitivity results)
    - The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, **AND** medical necessity for continued use

**AR** - Cefaclor Suspension: a PA is required for patients 12 years and older

**AR** - Cefixime Suspension: a PA is required for patients 12 years and older

**AR** - Cefprozil Suspension: a PA is required for patients 12 years and older

**AR** - Suprax Chewable Tablet: a PA is required for patients 12 years and older

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=75)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=25)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
